Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smoking cessation

This article was originally published in The Tan Sheet

Executive Summary

Providing more "pharmacological options to smokers can increase the number of treatment-assisted quit attempts," CDC editors state in the July 28 Morbidity & Mortality Weekly Report. A study examining sales of Rx and OTC smoking cessation items - patches, gums, inhalers, nasal sprays and non-nicotine Rx drugs - shows the number of smokers attempting to quit using drug therapy increases when a new product is introduced and when existing products are switched to OTC status. Conducted at the University of Pittsburgh, the study was sponsored by Nicorette and NicoDerm CQ marketer SmithKline Beecham. The editors note the report is based on sales rather than actual usage, that Rx and OTC sales are not tallied the same way and that externalities such as cigarette price increases and public policy were not considered

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel